News

Univercells Technologies Debuts the scale-X™ Nitro Controller to Expand Access to Large-Scale Viral and Advanced Therapy Manufacturing
Univercells Technologies, a Donaldson Life Sciences business and global provider of bioprocessing solutions, announced the ...
Contract Pharma1d
Univercells Launches Scale-X Nitro Controller
Univercells Technologies has launched the scale-X nitro controller, the latest addition to its scale-X fixed-bed bioreactor ...
Newbiologix Licenses Xcell-Eng-HEK293 Cell Line To Recibiopharm For Development And Manufacture Of Adeno-Associated Virus (AAV) Therapeutics
Provides ReciBioPharm's customers with access to NewBiologix's Xcell-Eng-HEK293 cell lines for advanced therapies <l ...
Dynavax Technologies: Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs
Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine ...
Morningstar3d
Univercells Technologies Debuts the scale-X™ Nitro Controller to Expand Access to Large-Scale Viral and Advanced Therapy Manufacturing
it is suited for a wide range of applications including viral vaccines, exosomes, LV and AAV vector production, oncolytic viruses and recombinant proteins. “When we introduced the scale-X ...
Le Lézard5d
Matica Biotechnology and Texas A&M's NCTM Form Strategic Partnership to Deliver End-to-End Support for Cell and Gene Therapy Innovators
Matica Biotechnology, a specialized contract development and manufacturing organization (CDMO) for cell and gene therapies (CGT), has entered into a strategic partnership with the National Center for ...
Scientific Research Publishing23h
Recombinant IgM expression in mammalian cells: A target protein challenging biotechnological production ()
Additionally the IgM class might be useful as vaccine adjuvant as it acts as soluble toll-like ... drawback has been identified in comparison to the classical IgG molecule. Recombinant production of ...